

***Salmonella* Typhimurium uses anaerobic respiration to overcome propionate-mediated colonization resistance**

Catherine D. Shelton^{1§}, Woongjae Yoo^{1§}, Nicolas G. Shealy¹, Teresa P. Torres¹, Jacob K. Zieba¹, M. Wade Calcutt², Nora J. Foegeding¹, Dajeong Kim³, Jinshil Kim^{3,4}, Sangryeol Ryu^{3,4}, Mariana X. Byndloss^{1,5,6*}

¹Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, U.S.A.

²Mass Spectrometry Research Center and Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, U.S.A.

³Department of Food and Animal Biotechnology, Department of Agricultural Biotechnology, and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 08826, Republic of Korea

⁴Center for Food Bioconvergence, Seoul National University, Seoul 08826, Republic of Korea

⁵Vanderbilt Institute of Infection, Immunology, and Inflammation, Vanderbilt University Medical Center, Nashville, TN 37232, U.S.A.

⁶Vanderbilt Digestive Disease Center, Vanderbilt University Medical Center, Nashville, TN 37232, U.S.A.

[§]Authors contributed equally

* Lead correspondence: mariana.x.byndloss@vumc.org

29 SUMMARY

30
31 The gut microbiota benefits the host by limiting enteric pathogen expansion (colonization resistance) partially via
32 the production of inhibitory metabolites. Propionate, a short-chain fatty acid produced by microbiota members,
33 is proposed to mediate colonization resistance against *Salmonella enterica* serovar Typhimurium (*S. Tm*). Here,
34 we show that *S. Tm* overcomes the inhibitory effects of propionate by using it as a carbon source for anaerobic
35 respiration. We determined that propionate metabolism provides an inflammation-dependent colonization
36 advantage to *S. Tm* during infection. Such benefit was abolished in the intestinal lumen of *Salmonella*-infected
37 germ-free mice. Interestingly, *S. Tm* propionate-mediated intestinal expansion was restored when germ-free
38 mice were monocolonized with *Bacteroides thetaiotaomicron* (*B. theta*), a prominent propionate producer in the
39 gut, but not when mice were monocolonized with a propionate production-deficient *B. theta* strain. Taken
40 together, our results reveal a novel strategy used by *S. Tm* to mitigate colonization resistance by metabolizing
41 microbiota-derived propionate.

42 43 **Keywords**

44 gut microbiota; *Salmonella*; propionate; intestinal inflammation

56

57 MAIN TEXT

58

59 Introduction

60 The intestines are occupied by a complex microbial community, the gut microbiota, mainly composed of
61 obligate anaerobic bacteria. By residing in the gut, the microbiota contributes to host health through nutrient
62 production (1, 2), immune education (3, Reviewed in 4), and protection against enteric pathogens (colonization
63 resistance) (5, 6). Colonization resistance is accomplished through diverse mechanisms (7). For instance, the
64 gut microbiota can indirectly inhibit pathogen expansion by activating the host's immune response or by
65 enhancing the intestinal mucosal barrier (8, 9, 10). On the other hand, direct antagonism of enteric pathogens
66 by the gut microbiota is achieved through niche competition or the production of inhibitory molecules (11, 12).

67 A proposed microbiota-derived metabolite that mediates colonization resistance is propionate (13, 14).
68 Propionate, an abundant short-chain fatty acid (15), is generated by the fermentation of sugars by anaerobic
69 bacteria, specifically members of the *Bacteroides* genus (16). As a predicted component of colonization
70 resistance, propionate has previously been studied for its specific role in inhibiting *Salmonella enterica* serovar
71 Typhimurium (*S. Tm*). The complete mechanism by which propionate exerts its toxic effect on *S. Tm* remains
72 unknown. Initially, propionate was shown to inhibit *S. Tm* by generating toxic by-products produced during
73 propionate catabolism (14). Propionate was recently shown to acidify the intracellular space of *S. Tm* and
74 significantly reduce the *S. Tm*'s growth rate (13). However, the mechanisms employed by enteric pathogens to
75 overpower propionate-mediated colonization resistance, a key step for successful gut colonization, remain
76 largely unknown.

77 *S. Tm* has evolved several mechanisms to overcome colonization resistance. Upon infection, *S. Tm*
78 invades the intestinal epithelium and activates the host's innate immune system and inflammatory response (17).
79 As a result, the host produces reactive nitrogen species (RNS), specifically nitric oxide, to inhibit the growth of
80 the pathogen (18). Host-generated nitric oxide can react with other compounds in the intestinal lumen to generate
81 nitrate (19, 20). Interestingly, *S. Tm* can take advantage of the nitrate generated by the host immune response
82 by using it as an alternative electron acceptor to fuel anaerobic respiration (21). By performing anaerobic
83 respiration, *S. Tm* can outgrow the resident microbiota whose metabolism relies on fermentation (22, 23). In

84 addition to the energetic benefits of anaerobic respiration compared to fermentation, *S. Tm*'s metabolic adaption
85 in the inflamed gut enables the pathogen to access new nutrient niches and metabolize novel carbon sources
86 (24, 25).

87 The carbon sources utilized by *S. Tm* during anaerobic respiration remain largely uncharacterized.
88 Interestingly, is it possible that *S. Tm* may use propionate as a carbon source during infection, as this pathogen
89 possesses the machinery necessary for propionate catabolism (26, 27). Specifically, the *prpBCDE* operon
90 encodes the enzymes required to convert propionate into pyruvate through the 2-methylcitrate cycle (27).
91 Furthermore, genes in the *prp* operon are nonfunctional in extraintestinal serovars of *S. Tm*, raising the possibility
92 that propionate metabolism is required for successful *S. Tm* colonization in the inflamed intestinal lumen (28). In
93 this study, we show that the ability of *S. Tm* to metabolize propionate relies on nitrate-dependent anaerobic
94 respiration. We then use conventional and germ-free mouse models of *S. Tm* gastroenteritis to demonstrate
95 that *S. Tm* uses inflammation-dependent anaerobic respiration to overcome propionate-mediated colonization
96 resistance.

97 **Results**

98 **Propionate supports *S. Tm* growth during anaerobic respiration *in vitro*.**

99 Previous investigations into the function of the *prp* operon have focused on the use of propionate as a
00 carbon source under aerobic conditions (14, 29) (**Figure 1A and S1A**). However, as an enteric pathogen, *S. Tm*
01 encounters propionate in the intestinal lumen, which is mainly anaerobic (30). Therefore, we sought to investigate
02 the ability of *S. Tm* to metabolize propionate under conditions relevant to intestinal disease. We first determined
03 if propionate could support *S. Tm* growth *in vitro* if alternative electron acceptors (i.e., DMSO, TMAO, fumarate,
04 tetrathionate, nitrate) generated during *S. Tm*-induced inflammation were available (20, 28, 31) (**Figure 1B**).
05 Interestingly, we observed that propionate significantly increased *S. Tm* growth only when nitrate was added to
06 the media (**Figure 1B**). Propionate did not increase *S. Tm* growth when the other alternative electron acceptors
07 were added (**Figure 1B**). We next tested if a range of propionate concentrations (5 – 50 mM), physiologically
08 relevant for mice and humans (15, 16), supported *S. Tm* growth in the presence or absence of nitrate. *S. Tm*
09 was able to grow in increasing concentrations of propionate when nitrate was present in the media (**Figure 1C**),
10

11 suggesting that *S. Tm* may be able to metabolize high levels of propionate during infection. Notably, *S. Tm* could
12 not ferment propionate as no growth is observed in the absence of nitrate (**Figure 1C**).

13 To determine whether anaerobic respiration affects expression of the *prpBCDE* operon, we measured
14 changes in *S. Tm* gene transcription when propionate, nitrate, or propionate and nitrate were available.
15 Propionate alone induced expression of *prpR*, the transcriptional activator of the *prpBCDE* operon (**Figure 1D**).
16 However, addition of nitrate (nitrate + propionate media) was necessary to increase expression of the propionate
17 utilization genes *prpB* and *prpC* (**Figure 1E and 1F**), supporting the specific role of nitrate in propionate
18 catabolism. We next confirmed that the *prpBCDE* operon was necessary for *S. Tm* growth in the presence of
19 propionate and nitrate. Deletion of the *prpBCDE* operon or *prpC* in *S. Tm* blunted the pathogen's growth on
20 propionate under anaerobic respiration conditions (**Figure 1G, S1B, S1C**). However, no defects in growth were
21 observed when mutants were given glucose or glycerol as a carbon source (**Figure S1D and S1E**). Growth on
22 propionate could be restored in $\Delta prpC$ by reintroducing the *prpC* gene by plasmid complementation (**Figure 1G**).
23 These experiments reveal that nitrate respiration supports propionate catabolism *in vitro* through the *prpBCDE*
24 operon.

26 **Nitrate respiration allows *S. Tm* to overcome the inhibitory effects of propionate under low pH.**

27 The ability of *S. Tm* to use propionate as a carbon source under anaerobic respiration conditions may be
28 confounded by the acidifying effects of this short-chain fatty acid (13, 32), particularly in the low pH of the
29 intestines (ranging from pH 7.4 to 5.7) (33). Thus, we determined how changes in pH impact the growth of *S.*
30 *Tm* with propionate and nitrate *in vitro*. Notably, *S. Tm* grew significantly more at pH 7.0, pH 6.5, and pH 6.0
31 when propionate and nitrate were present than with propionate alone (**Figure 2A-C**). Wildtype *S. Tm* also grew
32 significantly better than $\Delta prpC$, which failed to grow when given propionate and nitrate at all pH values tested
33 (**Figure 2A-C**). The growth of wildtype *S. Tm* at pH 6.0 was reduced compared to growth at pH 6.5 and pH 7.0
34 (**Figure 2C**). However, decreased growth is observed when *S. Tm* is grown with glycerol and nitrate at pH 6.0,
35 suggesting that reduced growth at pH 6.0 is not specific to propionate metabolism (**Figure S2A and S2B**).

36 Previous research revealed that propionate mediated colonization resistance by decreasing the growth
37 rate of *S. Tm* (13). To address if nitrate prevented this effect of propionate, the generation time of *S. Tm* at pH
38 7.0, 6.5, and 6.0 was calculated when *S. Tm* was grown in the presence of propionate and nitrate or propionate

39 alone. The addition of nitrate significantly decreased the generation time of wildtype *S. Tm* at all pH values
40 tested (**Figure 2D-F**). Furthermore, the generation time of wildtype *S. Tm* was markedly shorter than $\Delta prpC$ at
41 each pH tested when propionate and nitrate were present (**Figure 2D-F**). Although nitrate led to a significant
42 reduction in generation time for $\Delta prpC$ at pH 6.5, no difference in generation time was observed at pH 7.0 and
43 pH 6.0 when both nitrate and propionate were available (**Figure 2D-F**). These data show that nitrate can mitigate
44 the inhibitory effects of propionate on *S. Tm* growth by promoting propionate metabolism through the *prpBCDE*
45 operon.

47 **Propionate metabolism provides a growth advantage to *S. Tm* in the inflamed gut.**

48 After discovering that *S. Tm* can metabolize propionate under anaerobic respiration conditions *in vitro*,
49 we next investigated whether propionate catabolism provided *S. Tm* with a colonization advantage *in vivo*. We
50 infected C57BL/6 mice, pretreated with streptomycin, with an equal mixture of wildtype *S. Tm* and $\Delta prpC$. Four
51 days after infection, the bacterial load of each strain was determined by plating the colon contents on selective
52 media, and the ratio of *S. Tm* wildtype and $\Delta prpC$ (competitive index) was calculated. To determine the role of
53 propionate catabolism in *S. Tm* colonization of systemic sites, we also assessed *S. Tm* wildtype vs. $\Delta prpC$ mutant
54 competitive index in spleen and liver sampled from infected mice. Interestingly, we observed a significant
55 competitive advantage for WT *S. Tm* over $\Delta prpC$ in the colon contents, but not in the liver or spleen (**Figure 3A**).
56 These experiments reveal that propionate metabolism benefits *S. Tm* during infection specifically in the
57 gastrointestinal tract.

58 Next, we investigated whether inflammation was required for propionate metabolism to confer an
59 advantage to *S. Tm*. C57BL/6 mice, pretreated with streptomycin, developed significant intestinal inflammation
60 characterized by edema, epithelial damage, infiltration of inflammatory cells in the submucosa and exudate in
61 the intestinal lumen four days after *S. Tm* infection (**Fig. 3C, D**). *S. Tm* uses two type III secretion systems (T3SS)
62 to invade the intestinal epithelium and perform intracellular replication (17). A mutant strain ($\Delta invA \Delta spiB$) of *S.*
63 *Tm* is defective in both T3SS and does not cause inflammation in a mouse model (34, 35). Thus, we constructed
64 an $\Delta prpC$ mutant in the *S. Tm* inflammation-deficient background ($\Delta invA \Delta spiB \Delta prpC$) and then infected
65 streptomycin pretreated C57BL/6 mice with an equal mixture of $\Delta invA \Delta spiB$ and $\Delta invA \Delta spiB \Delta prpC$. The

66 competitive index was determined four days after infection. In contrast to the competitive advantage observed
67 for wildtype over $\Delta prpC$, no competitive advantage was observed for $\Delta invA \Delta spiB$ over $\Delta invA \Delta spiB \Delta prpC$,
68 revealing that inflammation is required for propionate metabolism to be advantageous to *S. Tm* (**Figure 3B**).
69 Histopathology analysis confirmed that infection with *S. Tm* $\Delta invA \Delta spiB$ did not induce intestinal inflammation
70 (**Fig. 3C, D**). The concentration of propionate was measured in the feces of mice infected with wildtype or $\Delta invA$
71 $\Delta spiB$ and no significant differences were observed (**Figure 3E**), indicating that the lack of an advantage of $\Delta invA$
72 $\Delta spiB$ over $\Delta invA \Delta spiB \Delta prpC$ was not due to decreased levels of propionate in $\Delta invA \Delta spiB$ -infected mice.

74 Nitrate respiration is required for *S. Tm* to benefit from propionate metabolism *in vivo*.

75 We observed *in vitro* that the only alternative electron acceptor that can support *S. Tm* growth on
76 propionate is nitrate (**Fig. 1**). To perform anaerobic respiration using nitrate as an alternative electron acceptor,
77 *S. Tm* relies on three nitrate reductases, *narGHI*, *narZYV*, *napABC* (36). Indeed, a $\Delta napA \Delta narZ \Delta narG$ mutant
78 strain of *S. Tm* is unable to perform nitrate-dependent anaerobic respiration (22, 36). To investigate if nitrate
79 respiration is required for propionate metabolism to be advantageous *in vivo*, we infected streptomycin pretreated
80 C57BL/6 mice with an equal mixture of *S. Tm* $\Delta napA \Delta narZ \Delta narG$ and *S. Tm* $\Delta napA \Delta narZ \Delta narG \Delta prpC$ and
81 measured the competitive index four days after infection. In contrast to the competitive advantage observed for
82 wildtype over $\Delta prpC$, no advantage was observed for $\Delta napA \Delta narZ \Delta narG$ over $\Delta napA \Delta narZ \Delta narG \Delta prpC$
83 (**Figure 4A**), suggesting that nitrate respiration is required for propionate metabolism to benefit *S. Tm in vivo*.

84 As an alternative approach, we investigated if propionate metabolism was advantageous to *S. Tm* if the
85 availability of inflammation-derived nitrate was decreased. During *Salmonella* infection, inflammatory monocytes
86 and intestinal epithelial cells upregulate inducible nitric oxide synthase (iNOS) encoded by *Nos2*, leading to the
87 production of nitric oxide (22, 23) (**Figure 4B**). Nitric oxide reacts with superoxide radicals to form peroxynitrate,
88 which can then decompose into nitrate (31). Therefore, we repeated the competitive infection assays in mice
89 treated with the iNOS inhibitor aminoguanidine (31), and in iNOS (*Nos2*)-deficient mice. In mock-treated wildtype
90 mice, we observed a competitive advantage for wildtype *S. Tm* over $\Delta prpC$ (**Figure 4C**). However, this advantage
91 was abrogated both in mice treated with aminoguanidine and in *Nos2*-deficient mice (**Figure 4C**). Nitrate
92 measurements from colonic and cecal mucosa revealed a significant decrease in nitrate levels in mice treated

93 with aminoguanidine and in *Nos2*-deficient mice (**Figure 4D**). Despite differences in nitrate levels, inflammation
94 was similar between the three treatment groups (**Figure 4E**). Propionate levels were similar in the feces of
95 aminoguanidine-treated mice and were elevated in the feces of *Nos2* $-/-$ mice compared to mock-treated wildtype
96 mice (**Figure 4F**), confirming that lack of a competitive advantage of wildtype *S. Tm* over $\Delta prpC$ in
97 aminoguanidine-treated or in *Nos2* $-/-$ mice was not due to decreased propionate or differences in inflammation
98 between experimental groups. Together, these data reveal that the host-derived nitrate supports propionate
99 utilization by *S. Tm* during pathogen-induced gastroenteritis.

01 **Microbiota-derived propionate provides a growth advantage to *S. Tm* in the presence of nitrate.**

02 While we predict that the advantage of wildtype *S. Tm* over $\Delta prpC$ (**Figure 3**) is due to the ability of
03 wildtype *S. Tm* to overcome propionate-mediated colonization resistance, it is possible that other microbiota-
04 derived metabolites may contribute to this phenotype. Therefore, we sought to examine the advantage of
05 wildtype versus $\Delta prpC$ using an *in vitro* approach in which propionate levels can be controlled. As a source of
06 propionate, we used *Bacteroides thetaiotaomicron*, a representative of the *Bacteroides* genus and a predominant
07 propionate producer in the gut (37). As a negative control, we also cultured *B. theta* BT1686-89, an isogenic
08 propionate production-deficient *B. theta* mutant strain (38). *B. theta* BT1686-89 was grown anaerobically in
09 mucin-broth for four days to adjust for a growth defect, while wildtype *B. theta* was grown for two days (**Figure**
10 **S3A and S3B**). Growth of wildtype *B. theta* led to an accumulation of propionate in the media while *B. theta*
11 BT1686-89 supernatant contained significantly less propionate (**Figure 5A**). Then, to determine whether
12 microbiota-derived propionate provides a growth advantage to *S. Tm*, we cultured wildtype *S. Tm* and *S. Tm*
13 $\Delta prpC$ in supernatant from wildtype *B. theta* or *B. theta* BT1686-89, and *B. theta* supernatants were either left
14 untreated or supplemented with nitrate (**Figure 5B-C**). In the absence of nitrate, no differences in growth were
15 observed between wildtype *S. Tm* or $\Delta prpC$ cultured in supernatant from either wildtype *B. theta* or *B. theta*
16 BT1686-89 (**Figure 5A**). However, addition of nitrate enabled wildtype *S. Tm* to grow to significantly higher levels
17 than $\Delta prpC$ in supernatant from wildtype *B. theta*, but not in supernatant from *B. theta* BT1686-89 (**Figure 5B-**
18 **C**). Restoring propionate levels in supernatant of *B. theta* BT1686-89 (**Figure 5A**) rescued wildtype *S. Tm*'s
19 ability to grow significantly more than $\Delta prpC$ in the presence of nitrate (**Figure 5B-C**). These results indicate that

20 the growth advantage of wildtype *S. Tm* over $\Delta prpC$ is specific to propionate and not due to other *B. theta*-derived
21 metabolites. Moreover, these results demonstrate that microbe-derived propionate can fuel *S. Tm* growth in the
22 presence of nitrate in a *prpBCDE*-dependent manner.

24 **Metabolism of *Bacteroides*-produced propionate supports *S. Tm* growth *in vivo*.**

25 To determine whether *Bacteroides*-produced propionate promotes *S. Tm* intestinal colonization *in vivo*,
26 we investigated the role of *S. Tm* propionate utilization during intestinal infection in a germ-free mouse model.
27 Germ-free mice were left germ-free or were colonized with wildtype *B. theta* or *B. theta* BT1686-89 (**Figure 6A**).
28 In addition, a subset of mice colonized with *B. theta* BT1686-89 were treated with propionate in their drinking
29 water (**Figure 6A**). Measurement of propionate in the feces of mice seven days after colonization revealed that
30 mice given wildtype *B. theta* had significantly higher levels of propionate than mice colonized with *B. theta*
31 BT1686-89 (**Figure 6B**). Supplementation with propionate in the drinking water of mice colonized with *B. theta*
32 BT1686-89 increased the amount of propionate in the feces (**Figure 6B**). Colonization of the three groups with
33 their respective strain of *Bacteroides* was confirmed after seven days (**Figure 6C**). Next, we infected each group
34 with an equal mixture of wildtype *S. Tm* and $\Delta prpC$. Wildtype *S. Tm* was able to outcompete the $\Delta prpC$ mutant
35 in mice colonized with wildtype *B. theta* three days after infection, (**Figure 6D-E**). The wildtype *S. Tm* competitive
36 advantage was abrogated in mice colonized with *B. theta* BT1686-89 but restored if *B. theta* BT1686-89 mice
37 are given propionate in the drinking water (**Figure 6D-E**). All experimental groups had equal levels of intestinal
38 inflammation, revealing that differences in propionate-dependent intestinal colonization by *S. Tm* in mice
39 colonized with wildtype *B. theta* or *B. theta* BT1686-89 were not due to altered host-immune responses (**Figure**
40 **6F**). Collectively, these experiments show that *S. Tm* can overcome the inhibitory effects of *Bacteroides*-derived
41 propionate in the inflamed gut.

43 **Discussion**

44 For decades, the antimicrobial properties of propionate have been leveraged to limit *Salmonellae*
45 infection in agricultural animals (32, 39). However, in this study, we report findings that *S. Tm* can overcome the
46 inhibitory effects of propionate if inflammation-derived nitrate is available. Our data show that *S. Tm* upregulates
47 machinery used to perform propionate catabolism if nitrate is present. This leads to an advantage *in vivo* as

48 strains of *S. Tm* that can perform propionate metabolism have an advantage over strains that cannot catabolize
49 propionate. Collectively, we describe a novel mechanism by which *S. Tm* contends with a component of
50 colonization resistance by performing anaerobic respiration in the inflamed gut (**Figure S4**).

51 A recent report determined that propionate production by gut microbiota members inhibited *S. Tm*
52 colonization *in vivo* (13). For the study, the researchers utilized a mouse model of chronic *S. Tm* infection,
53 characterized by lower bacterial burden and mild intestinal inflammation (13). In contrast, we investigated the
54 interaction between propionate and *S. Tm* in a mouse model of *S. Tm*- induced gastroenteritis that results in
55 severe inflammation (40) (**Figure 3C-D**). *S. Tm* causes inflammation by invading the intestinal epithelium and
56 triggering an immune response (17). Consequently, innate immune cells release reactive oxygen and nitrogen
57 species that react to generate alternative electron acceptors, including tetrathionate and nitrate (23, 31, 41). The
58 presence of alternative electron acceptors provides *S. Tm* with the opportunity to perform anaerobic respiration
59 and outgrow the obligate anaerobic microbiota (22, 23, 41). Furthermore, the inflamed gut is a unique niche in
60 which *S. Tm* alters its metabolism and begins to utilize carbon sources that require respiration (28). Some of
61 these carbon sources have been identified, including 1,2-propanediol, ethanolamine, and fructose-asparagine
62 (24, 25, 42). However, many remain unknown (28). Here, we show that *S. Tm* can metabolize propionate via
63 anaerobic respiration, and this provides *S. Tm* with an advantage *in vivo*. Interestingly, propionate utilization was
64 specific to the availability of nitrate *in vitro* and *in vivo*, supporting the idea that nitrate is involved in the regulation
65 of the *prpBCDE* operon. By utilizing a different model of *S. Tm* infection, we show a new mechanism by which
66 *S. Tm* mitigates the effects of propionate.

67 Multiple mechanisms have been proposed by which propionate inhibits *Salmonella* and other enteric
68 pathogens. Initial studies hypothesized that propionate reduced *S. Tm* growth through the generation and
69 accumulation of toxic intermediates (14). Subsequent research focused on the ability of propionate to diffuse
70 into the cytoplasm of the bacteria and decrease intracellular pH (13, 16). This is predicted to impede the ability
71 of *S. Tm* to colonize its host (13). Additional modes of inhibition include repression of *S. Tm* invasion through
72 destabilization of *hilD*, a regulator of *Salmonella* Pathogenicity Island 1 (SPI1) (43). However, past studies that
73 examined the inhibitory effects of propionate did not consider the presence of inflammation-derived alternative
74 electron acceptors. Indeed, we showed that the addition of nitrate to cultures containing propionate increased
75 the growth rate of *S. Tm* despite acidic conditions. Therefore, we propose that inflammation-derived nitrate

66 provides *S. Tm* with the ability to overcome propionate-induced toxicity. The impact of inflammation-dependent
67 propionate catabolism in regulation of *S. Tm* invasion remains to be explored.

68 By leveraging a mono-colonized germ-free mice model, we determined that the advantage observed for
69 wildtype *S. Tm* over a *prpC* deficient mutant is specific to microbiota-derived propionate. The 2-methylcitrate
80 cycle is fueled by 1,2-propanediol and propionate; both metabolites are produced by members of the microbiota
81 (25). A previous study identified that 1,2-propanediol fuels *S. Tm* growth during infection (25). In this work, we
82 showed that the advantage observed for wildtype *S. Tm* over a *prpC* deficient mutant is specific to propionate
83 and not 1,2-propanediol using germ-free mice colonized with the specific strains of *B. theta*. Future work should
84 examine how *S. Tm* integrates microbiota-derived 1,2-propanediol and propionate to grow *in vivo*.

85 In conclusion, this study shows that intestinal inflammation enables *S. Tm* to overcome propionate-
86 mediated colonization resistance. Together, our findings provide the paradigm-shifting perspective that, during
87 infection, microbiota-derived propionate may aid in intestinal pathogen colonization. Therefore, in addition to the
88 role of propionate in promoting colonization resistance, we propose that during infection, microbiota-derived
89 propionate may also support *S. Tm* expansion in the intestinal tract. The inhibitory and beneficial effects of
90 propionate during pathogen colonization may have significant implications on the use of microbiota-derived
91 propionate as an antimicrobial treatment during *S. Tm* gastroenteritis and will be an important area of future
92 research.

93 94 95 **Acknowledgments**

96
97 We would like to thank Dr. Eric Martens for kindly providing *Bacteroides thetaiotaomicron* and *Bacteroides*
98 *thetaitaomicron* BT1686-89. C.D.S. was supported by Dorothy Beryl and Theodore Roe Austin Pathology
99 Research Fund and T32AI112541. W.Y. was supported by the Basic Science Research Program through the
00 National Research Foundation of Korea (N.R.F.) by the Ministry of Education 2020R1A6A3A03037326. N.G.S.
01 was supported by T32ES007028-46. N.J.F. was supported by T32DK007673. Work in S.R.'s laboratory was
02 supported by a grant (19162MFDS037) from the Ministry of Food and Drug Safety of Korea, Korea in 2021. Work
03 in M.X.B.'s laboratory was supported by V Scholar grant V2020-013 from The V Foundation for Cancer

04 Research, Vanderbilt Digestive Disease Pilot and Feasibility grant P30 058404, A.C.S. Institutional Research
05 Grant IRG-19-139-59, VICC GI SPORE grant P50CA236733, United States-Israel Binational Science
06 Foundation grant 2019136 and Vanderbilt Institute for Clinical and Translational Research Grant VR53102.

07

08 **Author contributions**

09 M.X.B., C.D.S., W.Y., and S.R. designed and conceived the study. C.D.S., W.Y., N. S., T.T., J.Z., N.J.F., D.K.,
10 and J.K. performed all experiments. M.W.C. performed propionate measurements. All authors contributed to
11 the data analysis and preparation of the manuscript.

12

13 **Declaration of interests**

14 The authors declare no conflict of interest.

15

16

17 **FIGURE LEGENDS**

18

19 **Figure 1. Propionate fuels *S. Tm* growth in the presence of nitrate *in vitro*.** (A) Simplified model of propionate

20 catabolism in *S. Tm*. Genes in the *prpBCDE* operon (red) metabolize propionate into pyruvate. *prpE*, propionyl-

21 CoA synthase; *prpC*, methylcitrate synthase; *prpD*, methylcitrate dehydratase; *prpB*, 2-methylisocitrate lyase.

22 (B) NCE minimal media containing 40 mM of an alternative electron acceptor alone or 40 mM alternative electron

23 acceptor + 10 mM propionate was inoculated with *S. Tm* and grown anaerobically for 24 hours. Fold change

24 calculated by comparing growth of alternative electron acceptor + 10 mM propionate to growth with alternative

25 electron acceptor alone. (C) NCE minimal media containing increasing propionate concentration with or without

26 40 mM nitrate was inoculated with *S. Tm*. OD₆₀₀ of *S. Tm* was measured after 24 hours of anaerobic growth. (D

27 – F) Relative transcription of *prpR* (D), *prpB* (E), *prpC* (F) in NCE minimal media supplemented with propionate,

28 nitrate, or both propionate and nitrate was determined by qRT-PCR. Transcription of target genes was

29 normalized to *gyrB* rRNA. (G) NCE minimal media containing propionate or propionate and nitrate was

30 inoculated with wildtype *S. Tm*, $\Delta prpC$, or a complemented strain of $\Delta prpC$ ($\Delta prpC_pprpC$). Media was

31 supplemented with 200 μ M Isopropyl β -D-1-thiogalactopyranoside (IPTG) to induce expression of *prpC* in the

32 complemented mutant strain. OD₆₀₀ of each strain was measured after 24 hours of anaerobic growth. Each dot

33 represents one biological replicate. Bars represent the geometric mean. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$;

34 ****, $p < 0.0001$; ns, not statistically significant. See also Figure S1.

35

36 **Figure 2. Nitrate prevents inhibitory effects of propionate on *S. Tm in vitro*.** (A-C) NCE minimal media was

37 adjusted to pH 7.0 (A), pH 6.5 (B), and pH 6.0 (C). Media was supplemented with 10 mM propionate or 10 mM

38 propionate + 40 mM nitrate and inoculated with wildtype *S. Tm* or $\Delta prpC$. The culture was grown anaerobically

39 for 14 hours, and samples were taken every two hours to plate for CFUs. N=4. (D-F) Cultures grown in A-C were

40 used to calculate the generation time of wildtype *S. Tm* or $\Delta prpC$ at pH 7.0 (D), pH 6.5 (E), pH 6.0 (F). Each

41 dot represents one biological replicate. Bars represent the geometric mean. *, $p < 0.05$; **, $p < 0.01$; ****, $p <$

42 0.0001. See also Figure S2.

43

44 **Figure 3. Propionate utilization confers an advantage to *S. Tm* in an inflammation-dependent mechanism.**

45 (A) Streptomycin-pretreated C57BL/6 mice were inoculated with an equal mixture of wildtype *S. Tm* and $\Delta prpC$.
46 The competitive index in the colon content and homogenized samples from the liver or spleen was determined
47 four days after infection. (B) Streptomycin-pretreated C57BL/6 mice were inoculated with an equal mixture of the
48 indicated *S. Tm* strains. The competitive index in the colonic content was determined four days after infection.
49 (C) Combined histopathology score of pathological lesions in the cecum of mice from (B). (D) Representative
50 images of Hematoxylin and Eosin-stained cecal tissue of mice from (C). Scale bar equals 200 μ m. (E) Propionate
51 concentration in the cecal content was determined by liquid chromatography/ mass spectrometry (LC/MS) two
52 days after infection. Each dot represents one animal. Bars represent the geometric mean. *, $p < 0.05$; **, $p <$
53 0.01 ; ***, $p < 0.001$; ****, $p < 0.0001$.

54
55 **Figure 4. Inflammation generated nitrate required for propionate catabolism by *S. Tm*.** (A) Streptomycin-

56 pretreated C57BL/6 mice were inoculated with an equal mixture of the indicated *S. Tm* strains. The competitive
57 index in the colon content was determined four days after infection. (B) Streptomycin-pretreated C57BL/6 mice
58 were inoculated with *S. Tm* or mock-treated. mRNA levels of *Nos2* were measured in the cecal mucosa 4 days
59 post-infection and normalized to β -actin mRNA levels. (C) Streptomycin-pretreated C57BL/6 wildtype mice and
60 *Nos2*-deficient mice were inoculated with an equal mixture of the wildtype *S. Tm* and $\Delta prpC$ mutant. One group
61 was treated with aminoguanidine as indicated. The competitive index in the cecal content was determined four
62 days post-infection. (D) Nitrate concentration in the colonic mucus layer was determined in wildtype mice,
63 wildtype mice treated with aminoguanidine, and *Nos2*-deficient mice by a modified Griess assay. (E) Combined
64 histopathology score of pathological lesions in the cecum of mice from (C). (F) Propionate concentration in the
65 cecal content was determined by liquid chromatography/ mass spectrometry (LC/MS) two days after infection.
66 Each dot represents one animal. Bars represent the geometric mean. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$;
67 ****, $p < 0.0001$.

68
69 **Figure 5. *Bacteroides* produced propionate is a carbon source for *S. Tm* if nitrate is present.** (A-C) Mucin

70 broth was inoculated with wildtype *B. thetaiotaomicron* (WT) or *B. thetaiotaomicron* BT1686-89 (BT1686-89). *B.*
71 *theta* BT1686-89 was cultured anaerobically for 4 days and wildtype *B. theta* was cultured for 2 days. (A)

72 Propionate concentration in the digested mucin broth from WT or BT1686-89 *B. theta* culture (supplemented or
73 not with propionate) was determined by liquid chromatography/ mass spectrometry (LC/MS). (B) Filter-sterilized
74 wildtype *B. theta* or *B. theta* BT1686-89-digested mucin broth was inoculated with an equal mixture of wildtype
75 *S. Tm* and $\Delta prpC$. 40 mM nitrate and 10 mM propionate were added where indicated. Cultures were plated after
76 16 hours of anaerobic growth. (C) Competitive index was calculated from CFU counts in (A). Nitrate and
77 propionate were added as indicated. Each dot represents one biological replicate. Bars represent the geometric
78 mean. **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$. See also Figure S5.

79
80 **Figure 6. S. Tm utilization of microbiota-derived propionate provides an advantage during infection. (A)**

81 Schematic representation of the experiment and groups used. Germ-free mice were colonized with either
82 wildtype *B. theta* (WT) or *B. theta* BT1686-89 for 7 days before infection with an equal mixture of wildtype *S. Tm*
83 and a $\Delta prpC$ mutant. (B) Propionate concentration in the feces was measured after 7 days of colonization with
84 different strains of *Bacteroides* and propionate supplementation. (C) Before infection, fecal samples were
85 collected from monocolonized mice and plated on blood agar to confirm equal colonization between different
86 *Bacteroides* strains. (D) Monocolonized mice were infected with an equal mixture of the wildtype *S. Tm* and
87 $\Delta prpC$ mutant. The abundance of each strain in the colon content was determined by selective plating three days
88 post-infection. (E) Competitive index was calculated from CFU counts in (D). (F) Combined histopathology score
89 of pathological lesions in the cecum of mice from (D). Each dot represents one animal. Bars represent the
90 geometric mean. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

01 **Material and Methods**

03 **Contact for reagent and resource sharing**

04 Further information and requests for resources and reagents should be directed to and will be fulfilled by the
05 Lead Contact, Mariana X. Byndloss (mariana.x.byndloss@vumc.org). All unique reagents generated in this study
06 are available from the lead contact without restriction.

08 **Experimental models**

09 **Mouse husbandry**

10 All animal experiments were approved by the Institution of Animal Care and Use Committee at Vanderbilt
11 University Medical Center. Female C57BL/6J mice and *Nos2*-deficient (on the C57BL/6J background), aged 6
12 weeks, were obtained from The Jackson Laboratory. Mice were housed in individually ventilated cages with *ad*
13 *libitum* access to chow and water. Germ-free (G.F.) Swiss Webster mice were initially purchased from Taconic
14 Farms and maintained by the investigators at Vanderbilt University Medical Center. Experiments in this study
15 were performed with 6-week-old male and female G.F. mice.

16 Animals were randomly assigned to treatment groups before experimentation. At the end of the
17 experiment, mice were humanely euthanized using carbon dioxide inhalation. Animals that had to be euthanized
18 for humane reasons before reaching the predetermined time point were excluded from the analysis.

20 **Bacterial culture**

21 *S. Tm* strains (**Table S1**) were routinely grown aerobically at 37 °C in L.B. Broth (10 g/L tryptone, 5 g/L
22 yeast extract, 10 g/L sodium chloride) or on L.B. agar plates (10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium
23 chloride, 15 g/L agar). When appropriate, L.B. agar plates and broth were supplemented with 100 µg/mL
24 streptomycin (Strep), 30 µg/mL chloramphenicol (Cm), 100 µg/mL carbenicillin (Carb), 50 µg/mL kanamycin
25 (Kan). *B. thetaiotaomicron* strains were cultured in an anaerobic chamber (85% nitrogen, 10% hydrogen, 5%
26 carbon dioxide, Coy Lab Products). *B. thetaiotaomicron* strains (**Table S1**) were routinely cultured on blood agar
27 plates (37 g/L brain heart infusion medium, 15 g/L agar, 50 mL sheep blood).

28

29 **Experimental procedure**

30 **Construction of bacterial strains and plasmids**

31 All *S. Tm* mutants were generated from the SL1344 parent strain. To construct a $\Delta prpC$ mutant, upstream
32 and downstream regions of approximately 0.5 kb in length were amplified by PCR and then purified. The pRDH10
33 suicide vector was digested with Sall, purified, and assembled with the *prpC* PCR fragments to form
34 pRDH10:: $\Delta prpC$. pRDH10:: $\Delta prpC$ was then transformed into *E. coli* S17-1 λpir . Conjugation was then performed
35 at 30°C, and exconjugants in which the suicide plasmid had integrated into the chromosome of *S. Tm* were
36 recovered on L.B. agar plates containing streptomycin and chloramphenicol. Subsequent sucrose selection was
37 performed on sucrose plates (5% sucrose, 10 g/L tryptone, 5 g/L yeast extract, 10 g/L sodium chloride, 15 g/l
38 agar) to select for a second crossover events. PCR was performed to detect events that lead to the unmarked
39 deletion of *prpC*. The $\Delta prpBCDE$ mutant strain was constructed as described above, but with primers designed
40 for regions upstream of *prpB* and downstream of *prpE* in order to create pRDH10:: $\Delta prpBCDE$. To generate $\Delta invA$
41 $\Delta spiB$, *invA* was deleted from SL1344 using the lambda red recombination method (44). The Kan^R cassette was
42 amplified from pKD13 using the primers with homology to upstream and downstream of *invA*. The resulting PCR
43 product was integrated into the *invA* region in a wildtype strain containing the plasmid pKD46, followed by the
44 selection of $\Delta invA$::Kan mutants. The Kan^R cassette was removed using the plasmid PCP20 (44). The double
45 mutant $\Delta invA \Delta spiB$ was then constructed by deleting *spiB* from $\Delta invA$ using lambda red recombination as
46 detailed previously. To generate $\Delta invA \Delta spiB \Delta prpC$, *prpC* was deleted from $\Delta invA \Delta spiB$ using the lambda red
47 recombination method as described above. To construct a $\Delta napA \Delta narG \Delta narZ \Delta prpC$ mutant, conjugation was
48 performed with $\Delta napA \Delta narG \Delta narZ$ (22) and S17-1 λpir transformed with pRDH10:: $\Delta prpC$. Exconjugants were
49 recovered on L.B. agar plates containing streptomycin, carbenicillin, and chloramphenicol, and then sucrose
50 selection was performed for second crossover events. PCR was performed to detect events that lead to the
51 unmarked deletion of *prpC*. To introduce selectable marker, the *phoN*::Kan^R or *phoN*::Cm^R mutation was
52 transduced by phage P22 HT *int-105* (45) into strains as indicated in Table S1. To complement the *prpC* deletion,
53 the *prpC* gene was amplified and then combined with the BamHI-digested pUHE21-2*lac*^q plasmid using Gibson
54 Assembly. The resulting plasmid was transformed into *E. coli* DH5 α , and selected for on L.B. agar plates

55 containing carbenicillin. Plasmid ligation was confirmed by PCR, and pUHE21-2*lacI*⁺::*prpC* was then transformed
56 into Δ *prpC*. *B. thetaiotaomicron* containing a deletion in genes BT1686-89 (*B. theta* BT1686-89) was constructed
57 previously (38), and both wildtype *B. thetaiotaomicron* VPI-5482 Δ *tdk* (*B. theta*) (46) and *B. theta* BT1686-89
58 strains were provided to the investigators by Dr. Eric Martens.

60 ***In vitro* growth assays**

61 Non-Carbon E Salts (NCE media) containing 3.94 g/l monopotassium phosphate, 5.9 g/l dipotassium
62 phosphate, 4.68 g/l ammonium sodium hydrogen phosphate tetrahydrate, 2.46 g/l magnesium sulfate
63 heptahydrate, 1 mM magnesium sulfate, 0.1% casamino acids, 1% vitamin and mineral supplements (A.T.C.C.)
64 was supplemented with 40 mM of an electron acceptor (dimethyl sulfoxide (DMSO), trimethylamine N-oxide
65 (TMAO), fumarate, potassium tetrathionate, or sodium nitrate) or a combination of 10 mM propionate and an
66 electron acceptor. Media was placed in the anaerobic chamber 48 hours prior to inoculation. Overnight aerobic
67 cultures of *S. Tm* strains were harvested, washed in PBS, and resuspended in NCE media. wildtype *S. Tm* was
68 then added to anaerobic media containing different electron acceptors (plus or minus propionate) at a final
69 concentration of 1×10^4 CFU/mL. Growth was determined after 24 hours by spreading serial ten-fold dilutions on
70 LB agar plates.

71 To measure anaerobic growth of wildtype *S. Tm*, Δ *prpC*, and Δ *prpBCDE* with propionate and/or nitrate,
72 overnight cultures of each strain were diluted into anaerobic NCE media containing 40 mM glycerol and sodium
73 nitrate. Strains were incubated for four hours, harvested, washed in PBS, and resuspended in NCE media. In a
74 96 well plate, strains were added to NCE media containing propionate, nitrate, or a combination of both at a final
75 $OD_{600} = 0.001$. OD_{600} was measured after 24 hours using the Epoch 2 plate reader (BioTek). Similarly, growth of
76 wildtype *S. Tm*, Δ *prpC*, and Δ *prpBCDE* in NCE media containing 40 mM glycerol and nitrate or 5 mM glucose
77 was determined as described above with the exception that no anaerobic back-dilution was done.

78 To confirm growth of a complemented Δ *prpC* strain, overnight cultures of wildtype *S. Tm* + pUHE21-
79 2*lacI*⁺, Δ *prpC* + pUHE21-2*lacI*⁺, and Δ *prpC* + pUHE21-2*lacI*⁺::*prpC* were harvested, washed in PBS, and
80 resuspended in NCE media. Strains were then added to NCE media containing 200 μ M isopropyl β -D-1-
81 thiogalactopyranoside (IPTG) and 10 mM propionate or 200 μ M IPTG, 10 mM propionate, and 40 mM nitrate at

82 a final O.D. = 0.001. OD₆₀₀ was measured after 24 hours using the Epoch 2 plate reader (BioTek). *In vitro* growth
83 assays were performed in triplicate with different colonies.

85 ***In vitro* gene expression**

86 Overnight cultures of wildtype *S. Tm* were harvested and 1 x 10⁹ CFU was added to 5 mL of NCE media
87 or NCE media supplemented with either 10 mM propionate, 40 mM nitrate, or a combination of both. Cultures
88 were incubated for 4 hours prior to R.N.A. extraction (performed according to instructions for SurePrep TrueTotal
89 RNA Purification Kit). R.N.A. (500 ng) was reverse transcribed using an iScript gDNA Clear cDNA synthesis kit
90 (Bio-Rad). Quantitative PCR was performed using S.Y.B.R. green (SsoAdvanced; Bio-Rad) for *prpR*, *prpB*, and
91 *prpC*. The expression of target genes was normalized to that of *gyrB*. Primers are listed in **Table S2**.

93 **Growth and generation time of *S. Tm* at decreasing pH**

94 NCE media was adjusted to pH 7.0, pH 6.5, and pH 6.0 using 10 M hydrochloric acid (HCl). 10 mL of
95 media from each pH was supplemented with 10 mM propionate or 10 mM propionate + 40 mM nitrate and placed
96 in the anaerobic chamber. Overnight cultures of wildtype *S. Tm* and $\Delta prpC$ were washed in PBS and
97 resuspended in NCE media. Cultures were adjusted to an O.D. = 0.1 and then diluted 1:100 into pH-adjusted
98 media. Samples were incubated at 37 °C, and aliquots were removed every two hours for 14 hours. Aliquots
99 were then serially diluted and plated onto LB agar to determine bacterial numbers. Generation time (G) was
00 calculated according to (47) and using the following formula: $G = (T_2 - T_1) / (3.3 \log(B_2/B_1))$ where T_2 equals the
01 time at the end of exponential phase, and T_1 is the time at the beginning of the exponential phase. B_2 corresponds
02 to the bacterial number at T_2 , and B_1 equals the bacterial number at T_1 .

04 **Growth of *Bacteroides thetaiotaomicron* strains in mucin broth**

05 Porcine mucin was dissolved in 1x NCE salts at a final concentration of 0.5% (w/v). Mucin broth was
06 inoculated with a fresh colony of *B. theta* BT1686-89 and incubated under anaerobic conditions for 96 hours at
07 37°C or inoculated with wildtype *B. theta* and incubated for 48 hours at 37°C. To measure the growth of *B. theta*
08 BT1686-89, aliquots were removed from cultures, and ten-fold serial dilutions were plated on blood agar plates

to calculate bacterial numbers. Digested mucin broth from each strain was filter-sterilized (0.5 μm pore size) before propionate measurements or competitive growth assays.

Competitive growth assays

Competition assays were performed in either digested mucin broth or NCE Media. Propionate (10 mM) or nitrate (40 mM) were added as indicated. A 1:1 ratio of two overnight bacterial strains at a final concentration of 1×10^4 CFU/mL were added to the media and incubated anaerobically for 18 hours. Bacterial numbers were determined by plating serial dilutions on selective LB Agar plates. *In vitro* competition assays were performed in triplicate with different colonies

Animal experiments

Streptomycin-treated mouse model: Groups of 6 – 7-week-old C57BL/6 mice were treated with 5 g/L streptomycin in the drinking water for 48 hours which was then removed 24 hours before infection with *S. Tm*. For competitive infections, mice were orally inoculated with a 1:1 mixture of 1×10^9 CFU of each strain. Fecal samples were collected two days after infection for propionate measurement. Four days after infection, samples for histopathology, cecal tissue for RNA extraction, colonic luminal content for bacterial plating, and cecal content for propionate measurements were collected. In some experiments, mice were given 1 g/L aminoguanidine hydrochloride in their drinking water immediately after infection with *S. Tm*.

Germ-Free Swiss Webster mice: Groups of 6-week-old germ-free mice were colonized with approximately 1×10^8 CFU of wildtype *B. theta* or *B. theta* BT1686-89. Four days after colonization a subset of mice colonized with *B. theta* BT1686-89 were given 20 mM propionate in the drinking water. After 7 days, fecal samples were collected from mono-colonized mice to measure *B. theta* colonization and propionate levels. Mono-colonized and germ-free mice were then infected with an equal mixture of 1×10^7 CFU of wildtype *S. Tm* and $\Delta prpC$. Three days after infection with *S. Tm* samples were collected as described above.

Nitrate measurements

36 Intestinal nitrate measurements were performed as described previously (48). Briefly, mice were
37 euthanized, and the intestine was removed and divided along its sagittal plane. The mucus layer was gently
38 scraped from the tissue and homogenized in 200 μ l PBS and then placed on ice. Samples were centrifuged at
39 5,000 \times g for 10 min at 4°C to remove the remaining solid particles. The supernatant was then filter sterilized
40 (0.2- μ m pore size). Measurement of intestinal nitrate followed an adaptation of the Griess assay. In this assay,
41 nitrate was first reduced to nitrite by combining 50 μ l of each sample with 50 μ l of Griess reagent 1 containing
42 vanadium(III) chloride (0.5 M HCl, 0.2 mM VCl₃, 1% sulfanilamide), and then the mixture was incubated at room
43 temperature for 10 min. Next, 50 μ l of Griess reagent 2 [0.1% (1-naphthyl)ethylenediamine dichloride] was added
44 to each sample. Absorbance at 540 nm was measured immediately after the addition of Griess reagent 2 to
45 detect any nitrite present in the samples. The samples were then incubated for 8 h at room temperature (to allow
46 for reduction of nitrate to nitrite), and the absorbance at 540 nm was measured again. The initial absorbance
47 (prior to reducing nitrate to nitrite) was subtracted from the absorbance after 8 h to determine nitrate
48 concentrations in the mucus layer.

50 **Quantification of *Nos2* expression by qRT-PCR**

51 Cecal tissue was homogenized using a FastPrep-24 and RNA extracted using the TRI reagent method.
52 RNA (1 μ g) was reverse transcribed using an iScript gDNA Clear cDNA synthesis kit (Bio-Rad). Quantitative
53 PCR was performed with SYBR green (SsoAdvanced; Bio-Rad) for *Nos2* (Primers listed in **Table S2**). The
54 expression of *Nos2* was normalized to the housekeeping gene *Act2b*, encoding β -actin.

56 **Propionate measurements**

57 Extraction and normalization. Fecal matter was weighed, diluted to a final density of 0.125 g/mL in
58 MeOH/H₂O (1:5) and homogenized with a cordless *Pellet Pestle* tissue grinder equipped with disposable
59 polypropylene mixers (Fisher). Insoluble debris was removed by centrifugation (12,000 \times g, 30 min, 5 °C); the
60 supernatants were transferred to clean Eppendorf tubes and stored at -20 °C until the day of analysis.

61 Propionate Analysis. Propionate was derivatized with the reagent dansylhydrazine and the carboxyl
62 activating agent 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and measured as its corresponding
63 dansylhydrazone derivative (49). Briefly, fecal extracts (10 μ l) were spiked with a stable isotope-labeled internal

64 standard propionate-d₅ (1 nmol) and derivatized in H₂O/DMSO (2:1) containing 50 mM sodium phosphate buffer
65 (pH = 4), 12.5 mg/mL dansylhydrazine, and 12.5 mg/mL EDC. Due to the limited stability of EDC in water, stock
66 solutions of EDC should be made up in ice-cold water and used immediately. After two hours at room
67 temperature, dansylated derivatives were extracted once with ethyl acetate (750 μL). The organic (top) layer
68 was transferred to a clean Eppendorf tube, dried under a gentle stream of nitrogen gas, and reconstituted in 150
69 μL of acetonitrile/water (1:1) prior to analysis. Calibration standards for unlabeled propionate were prepared in
70 water, derivatized, and extracted in the same manner. LC-MS/MS analysis was performed using a Thermo TSQ
71 Quantum mass spectrometer interfaced to a Thermo HTC PAL refrigerated autosampler and a Thermo Surveyor
72 HPLC pump. A Waters XTerra MS analytical column (2.1 mm x 100 mm, 3.5 μm) was used for all
73 chromatographic separations. Mobile phases were made up of 0.2% acetic acid and 15 mM ammonium acetate
74 in (A) H₂O/CH₃CN (9:1) and in (B) CH₃CN/CH₃OH/H₂O (90:5:5). Gradient conditions were as follows: 0–1 min,
75 B = 0 %; 1–8 min, B = 0–100 %; 8–10 min, B = 100 %; 10–10.5 min, B = 100–0 %; 10.5–15 min, B = 0 %. The
76 flow rate was maintained at 300 μL/min; a software-controlled divert valve was used to transfer eluent from 0–
77 2.0 min of each chromatographic run to waste. The total chromatographic run time was 15 min. The autosampler
78 tray temperature and the column compartment temperature were maintained at 5 °C and 50 °C respectively.
79 The sample injection volume was 10 μL. The autosampler injection valve and the sample injection needle were
80 flushed and washed sequentially with mobile phase B (two cycles) and mobile phase A (two cycles) between
81 each injection. The mass spectrometer was operated in positive ion mode. Quantitation was based on single
82 reaction monitoring detection of the following dansylated analogues: propionate, *m/z* 322 → 235, C.E. 15;
83 propionate-d₅: *m/z* 327 → 235, C.E. 15. The following optimized source parameters were used for the detection
84 of analytes and internal standards. N₂ sheath gas 40 psi; N₂ auxiliary gas 5 psi; spray voltage 4 kV; capillary
85 temperature 300 °C; tube lens voltage 120 V; declustering voltage 20 V. Data acquisition and quantitative
86 spectral analysis were done using Thermo-Finnigan Xcalibur version 2.0.7 SP1 and Thermo-Finnigan LCQuan
87 version 2.7, respectively. Calibration curves were constructed by plotting peak area ratios (analyte / internal
88 standard) against analyte concentrations for a series of nine calibration standards, ranging from 0.01 to 100 nmol
89 propionate. A weighting factor of 1/C² was applied in the linear least-squares regression analysis to maintain
90 homogeneity of variance across the concentration range (%RE ≤ 15% at C > LLOQ).

91

92 **Histopathology scoring**

93 Formalin fixed cecal tissue sections were stained with hematoxylin and eosin, and a veterinary
94 pathologist performed a blinded evaluation using criteria shown in **Table S3** as described previously (50).
95 Representative images were taken using a Leica DM750 microscope and a Leica ICC50W camera.

96

97 **Quantification and statistical analysis**

98 Statistical data analysis was performed using Graphpad PRISM. Fold changes of ratios (bacterial
99 competitive index and mRNA levels), and bacterial numbers were transformed logarithmically prior to statistical
00 analysis. An unpaired Student's t test was used on the transformed data to determine whether differences
01 between groups were statistically significant ($p < 0.05$). When more than two treatments were used, statistically
02 significant differences between groups were determined by one-way ANOVA followed by Tukey's HSD test
03 (between > 2 groups). Significance of differences in histopathology was determined by a one-tailed non-
04 parametric test (Mann-Whitney).

05

06

07 REFERENCES

- 08
- 09 1. Sonnenburg, J.L., Xu, J., Leip, D.D., Chen, C.H., Westover, B.P., Weatherford, J., Buhler, J.D. and Gordon,
10 J.I., 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. *Science*, 307(5717), pp.1955-
11 1959.
- 12 2. Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I.
13 (2004). The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National*
14 *Academy of Sciences of the United States of America*, 101(44), 15718–15723.
15 <https://doi.org/10.1073/pnas.0407076101>
- 16 3. Lathrop, S. K., Bloom, S. M., Rao, S. M., Nutsch, K., Lio, C. W., Santacruz, N., Peterson, D. A.,
17 Stappenbeck, T. S., & Hsieh, C. S. (2011). Peripheral education of the immune system by colonic
18 commensal microbiota. *Nature*, 478(7368), 250–254. <https://doi.org/10.1038/nature10434>
- 19 4. Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and
20 disease. *Cell research*, 30(6), 492–506. <https://doi.org/10.1038/s41422-020-0332-7>
- 21 5. van der Waaij, D., Berghuis-de Vries, J. M., & Lekkerkerk Lekkerkerk-v (1971). Colonization resistance of
22 the digestive tract in conventional and antibiotic-treated mice. *The Journal of hygiene*, 69(3), 405–411.
23 <https://doi.org/10.1017/s0022172400021653>
- 24 6. Bohnhoff, M., Miller, C. P., & Martin, W. R. (1964). Resistance of the mouse's intestinal tract to experimental
25 Salmonella Infection. I. Factors which interfere with the initiation of off infection by oral inoculation. *The*
26 *Journal of experimental medicine*, 120(5), 805–816. <https://doi.org/10.1084/jem.120.5.805>
- 27 7. Sassone-Corsi, M., & Raffatellu, M. (2015). No Vacancy: How Beneficial Microbes Cooperate with Immunity
28 To Provide Colonization Resistance to Pathogens. *The Journal of Immunology*.
29 <https://doi.org/10.4049/jimmunol.1403169>
- 30 8. Petersson, J., Schreiber, O., Hansson, G. C., Gendler, S. J., Velcich, A., Lundberg, J. O., Roos, S., Holm,
31 L., & Phillipson, M. (2011). Importance and regulation of the colonic mucus barrier in a mouse model of
32 colitis. *American Journal of Physiology - Gastrointestinal and Liver Physiology*.
33 <https://doi.org/10.1152/ajpgi.00422.2010>

- 34 9. Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee,
35 C. A., Lynch, S. V., Tanoue, T., Imaoka, A., Itoh, K., Takeda, K., Umesaki, Y., Honda, K., & Littman, D. R.
36 (2009). Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria. *Cell*.
37 <https://doi.org/10.1016/j.cell.2009.09.033>
- 38 10. Benson, A., Pifer, R., Behrendt, C. L., Hooper, L. V., & Yarovinsky, F. (2009). Gut Commensal Bacteria
39 Direct a Protective Immune Response against *Toxoplasma gondii*. *Cell Host and Microbe*.
40 <https://doi.org/10.1016/j.chom.2009.06.005>
- 41 11. Deriu, E., Liu, J. Z., Pezeshki, M., Edwards, R. A., Ochoa, R. J., Contreras, H., Libby, S. J., Fang, F. C., &
42 Raffatellu, M. (2013). Probiotic bacteria reduce *Salmonella typhimurium* intestinal colonization by competing
43 for iron. *Cell Host and Microbe*. <https://doi.org/10.1016/j.chom.2013.06.007>
- 44 12. Sorbara, M. T., & Pamer, E. G. (2019). Interbacterial mechanisms of colonization resistance and the
45 strategies pathogens use to overcome them. *Mucosal immunology*, 12(1), 1–9.
46 <https://doi.org/10.1038/s41385-018-0053-0>
- 47 13. Jacobson, A., Lam, L., Rajendram, M., Tamburini, F., Honeycutt, J., Pham, T., Van Treuren, W., Pruss, K.,
48 Stabler, S. R., Lugo, K., Bouley, D. M., Vilches-Moure, J. G., Smith, M., Sonnenburg, J. L., Bhatt, A. S.,
49 Huang, K. C., & Monack, D. (2018). A Gut Commensal-Produced Metabolite Mediates Colonization
50 Resistance to *Salmonella* Infection. *Cell Host and Microbe*. <https://doi.org/10.1016/j.chom.2018.07.002>
- 51 14. Horswill, A. R., Dudding, A. R., & Escalante-Semerena, J. C. (2001). Studies of Propionate Toxicity in
52 *Salmonella enterica* Identify 2-Methylcitrate as a Potent Inhibitor of Cell Growth. *Journal of Biological*
53 *Chemistry*. <https://doi.org/10.1074/jbc.M100244200>
- 54 15. Byrne, B. M., & Dankert, J. (1979). Volatile fatty acids and aerobic flora in the gastrointestinal tract of mice
55 under various conditions. *Infection and immunity*, 23(3), 559–563. [https://doi.org/10.1128/IAI.23.3.559-](https://doi.org/10.1128/IAI.23.3.559-563.1979)
56 [563.1979](https://doi.org/10.1128/IAI.23.3.559-563.1979)
- 57 16. den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., & Bakker, B. M. (2013). The
58 role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy
59 metabolism. *Journal of lipid research*, 54(9), 2325–2340. <https://doi.org/10.1194/jlr.R036012>
- 60 17. Galán JE, Curtiss R III. 1989. Cloning and molecular characterization of genes whose products allow
61 *Salmonella typhimurium* to penetrate tissue culture cells. *P.N.A.S.* 86:6383–87

18. Alam, M. S., Akaike, T., Okamoto, S., Kubota, T., Yoshitake, J., Sawa, T., Miyamoto, Y., Tamura, F., & Maeda, H. (2002). Role of nitric oxide in host defense in murine salmonellosis as a function of its antibacterial and antiapoptotic activities. *Infection and immunity*, *70*(6), 3130–3142. <https://doi.org/10.1128/iai.70.6.3130-3142.2002>
19. Szabó, C., Ischiropoulos, H., & Radi, R. (2007). Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. *Nature reviews. Drug discovery*, *6*(8), 662–680. <https://doi.org/10.1038/nrd2222>
20. Rivera-Chávez, F., & Bäumler, A. J. (2015). The Pyromaniac Inside You: Salmonella Metabolism in the Host Gut. *Annual review of microbiology*, *69*, 31–48. <https://doi.org/10.1146/annurev-micro-091014-104108>
21. Barrett, E. L., & Riggs, D. L. (1982). Evidence of a second nitrate reductase activity that is distinct from the respiratory enzyme in *Salmonella typhimurium*. *Journal of bacteriology*, *150*(2), 563–571. <https://doi.org/10.1128/JB.150.2.563-571.1982>
22. Lopez, C. A., Winter, S. E., Rivera-Chávez, F., Xavier, M. N., Poon, V., Nuccio, S. P., Tsolis, R. M., & Bäumler, A. J. (2012). Phage-mediated acquisition of a type III secreted effector protein boosts growth of *Salmonella* by nitrate respiration. *mBio*, *3*(3), e00143-12. <https://doi.org/10.1128/mBio.00143-12>
23. McLaughlin, P. A., Bettke, J. A., Tam, J. W., Leeds, J., Bliska, J. B., Butler, B. P., & van der Velden, A. W. M. (2019). Inflammatory monocytes provide a niche for *Salmonella* expansion in the lumen of the inflamed intestine. *PLoS Pathogens*. <https://doi.org/10.1371/journal.ppat.1007847>
24. Thiennimitr, P., Winter, S. E., Winter, M. G., Xavier, M. N., Tolstikov, V., Huseby, D. L., Sterzenbach, T., Tsolis, R. M., Roth, J. R., & Bäumler, A. J. (2011). Intestinal inflammation allows *Salmonella* to use ethanolamine to compete with the microbiota. *Proceedings of the National Academy of Sciences of the United States of America*, *108*(42), 17480–17485. <https://doi.org/10.1073/pnas.1107857108>
25. Faber, F., Thiennimitr, P., Spiga, L., Byndloss, M. X., Litvak, Y., Lawhon, S., Andrews-Polymenis, H. L., Winter, S. E., & Bäumler, A. J. (2017). Respiration of Microbiota-Derived 1,2-propanediol Drives *Salmonella* Expansion during Colitis. *PLoS pathogens*, *13*(1), e1006129. <https://doi.org/10.1371/journal.ppat.1006129>
26. Horswill, A. R., & Escalante-Semerena, J. C. (1997). Propionate catabolism in *Salmonella typhimurium* LT2: Two divergently transcribed units comprise the *prp* locus at 8.5 centisomes, *prpR* encodes a member of the

- 89 sigma-54 family of activators, and the prpBCDE genes constitute an operon. *Journal of Bacteriology*.
90 <https://doi.org/10.1128/jb.179.3.928-940.1997>
- 91 27. Horswill, A. R., & Escalante-Semerena, J. C. (1999). Salmonella typhimurium LT2 catabolizes propionate
92 via the 2-methylcitric acid cycle. *Journal of Bacteriology*. <https://doi.org/10.1128/jb.181.18.5615-5623.1999>
- 93 28. Nuccio, S. P., & Bäumler, A. J. (2014). Comparative analysis of Salmonella genomes identifies a metabolic
94 network for escalating growth in the inflamed gut. *mBio*, 5(2), e00929-14.
95 <https://doi.org/10.1128/mBio.00929-14>
- 96 29. Rondon, M. R., Horswill, A. R., & Escalante-Semerena, J. C. (1995). D.N.A. polymerase I function is required
97 for the utilization of ethanolamine, 1,2-propanediol, and propionate by Salmonella typhimurium LT2. *Journal*
98 *of bacteriology*, 177(24), 7119–7124. <https://doi.org/10.1128/jb.177.24.7119-7124.1995>
- 99 30. Friedman, E. S., Bittinger, K., Esipova, T. V., Hou, L., Chau, L., Jiang, J., Mesaros, C., Lund, P. J., Liang,
00 X., FitzGerald, G. A., Goulian, M., Lee, D., Garcia, B. A., Blair, I. A., Vinogradov, S. A., & Wu, G. D. (2018).
01 Microbes vs. chemistry in the origin of the anaerobic gut lumen. *Proceedings of the National Academy of*
02 *Sciences of the United States of America*, 115(16), 4170–4175. <https://doi.org/10.1073/pnas.1718635115>
- 03 31. Winter, S. E., Winter, M. G., Xavier, M. N., Thiennimitr, P., Poon, V., Keestra, A. M., Laughlin, R. C., Gomez,
04 G., Wu, J., Lawhon, S. D., Popova, I. E., Parikh, S. J., Adams, L. G., Tsolis, R. M., Stewart, V. J., & Bäumler,
05 A. J. (2013). Host-derived nitrate boosts growth of E. coli in the inflamed gut. *Science*.
06 <https://doi.org/10.1126/science.1232467>
- 07 32. Ricke S. C. (2003). Perspectives on the use of organic acids and short chain fatty acids as
08 antimicrobials. *Poultry science*, 82(4), 632–639. <https://doi.org/10.1093/ps/82.4.632>
- 09 33. Sorbara, M. T., Dubin, K., Littmann, E. R., Moody, T. U., Fontana, E., Seok, R., Leiner, I. M., Taur, Y., Peled,
10 J. U., Van Den Brink, M. R. M., Litvak, Y., Bäumler, A. J., Chaubard, J. L., Pickard, A. J., Cross, J. R., &
11 Pamer, E. G. (2019). Inhibiting antibiotic-resistant Enterobacteriaceae by microbiota-mediated intracellular
12 acidification. *Journal of Experimental Medicine*. <https://doi.org/10.1084/jem.20181639>
- 13 34. Coombes, B. K., Coburn, B. A., Potter, A. A., Gomis, S., Mirakhur, K., Li, Y., & Finlay, B. B. (2005). Analysis
14 of the contribution of Salmonella pathogenicity islands 1 and 2 to enteric disease progression using a novel
15 bovine ileal loop model and a murine model of infectious enterocolitis. *Infection and immunity*, 73(11), 7161–
16 7169. <https://doi.org/10.1128/IAI.73.11.7161-7169.2005>

- 17 35. Raffatellu, M., George, M. D., Akiyama, Y., Hornsby, M. J., Nuccio, S. P., Paixao, T. A., Butler, B. P., Chu,
18 H., Santos, R. L., Berger, T., Mak, T. W., Tsolis, R. M., Bevins, C. L., Solnick, J. V., Dandekar, S., & Bäumler,
19 A. J. (2009). Lipocalin-2 resistance confers an advantage to *Salmonella enterica* serotype Typhimurium for
20 growth and survival in the inflamed intestine. *Cell host & microbe*, 5(5), 476–486.
21 <https://doi.org/10.1016/j.chom.2009.03.011>
- 22 36. Lopez, C. A., Rivera-Chávez, F., Byndloss, M. X., & Bäumler, A. J. (2015). The Periplasmic Nitrate
23 Reductase NapABC Supports Luminal Growth of *Salmonella enterica* Serovar Typhimurium during
24 Colitis. *Infection and immunity*, 83(9), 3470–3478. <https://doi.org/10.1128/IAI.00351-15>
- 25 37. Reichardt, N., Duncan, S. H., Young, P., Belenguer, A., McWilliam Leitch, C., Scott, K. P., Flint, H. J., &
26 Louis, P. (2014). Phylogenetic distribution of three pathways for propionate production within the human gut
27 microbiota. *The I.S.M.E. journal*, 8(6), 1323–1335. <https://doi.org/10.1038/ismej.2014.14>
- 28 38. Kovatcheva-Datchary, P., Nilsson, A., Akrami, R., Lee, Y. S., De Vadder, F., Arora, T., Hallen, A., Martens,
29 E., Björck, I., & Bäckhed, F. (2015). Dietary Fiber-Induced Improvement in Glucose Metabolism Is
30 Associated with Increased Abundance of *Prevotella*. *Cell metabolism*, 22(6), 971–982.
31 <https://doi.org/10.1016/j.cmet.2015.10.001>
- 32 39. Iba, A. M., & Berchieri, A., Jr (1995). Studies on the use of a formic acid-propionic acid mixture (Bio-add) to
33 control experimental *Salmonella* infection in broiler chickens. *Avian pathology: journal of the*
34 *W.V.P.A.*, 24(2), 303–311. <https://doi.org/10.1080/03079459508419071>
- 35 40. Barthel, M., Hapfelmeier, S., Quintanilla-Martínez, L., Kremer, M., Rohde, M., Hogardt, M., Pfeffer, K.,
36 Rüssmann, H., & Hardt, W. D. (2003). Pretreatment of mice with streptomycin provides a *Salmonella*
37 *enterica* serovar Typhimurium colitis model that allows analysis of both pathogen and host. *Infection and*
38 *immunity*, 71(5), 2839–2858. <https://doi.org/10.1128/iai.71.5.2839-2858.2003>
- 39 41. Winter, S. E., Thiennimitr, P., Winter, M. G., Butler, B. P., Huseby, D. L., Crawford, R. W., Russell, J. M.,
40 Bevins, C. L., Adams, L. G., Tsolis, R. M., Roth, J. R., & Bäumler, A. J. (2010). Gut inflammation provides
41 a respiratory electron acceptor for *Salmonella*. *Nature*, 467(7314), 426–429.
42 <https://doi.org/10.1038/nature09415>
- 43 42. Ali, M. M., Newsom, D. L., González, J. F., Sabag-Daigle, A., Stahl, C., Steidley, B., Dubena, J., Dyszel, J.
44 L., Smith, J. N., Dieye, Y., Arsenescu, R., Boyaka, P. N., Krakowka, S., Romeo, T., Behrman, E. J., White,


- 45 P., & Ahmer, B. M. (2014). Fructose-asparagine is a primary nutrient during growth of Salmonella in the
46 inflamed intestine. *PLoS pathogens*, 10(6), e1004209. <https://doi.org/10.1371/journal.ppat.1004209>
- 47 43. Hung, C. C., Garner, C. D., Slauch, J. M., Dwyer, Z. W., Lawhon, S. D., Frye, J. G., McClelland, M., Ahmer,
48 B. M., & Altier, C. (2013). The intestinal fatty acid propionate inhibits Salmonella invasion through the post-
49 translational control of HilD. *Molecular Microbiology*, 87(5), 1045–1060. <https://doi.org/10.1111/mmi.12149>
- 50 44. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using
51 PCR products. *Proc. Natl. Acad. Sci. USA*. **97**, 6640–6645, doi: 10.1073/pnas.120163297 (2000).
- 52 45. Schmieger H. Phage P22-mutants with increased or decreased transduction abilities. *Mol Gen*
53 *Genet.* 1972;119:75–88
- 54 46. Koropatkin, N. M., Martens, E. C., Gordon, J. I., & Smith, T. J. (2008). Starch catabolism by a prominent
55 human gut symbiont is directed by the recognition of amylose helices. *Structure (London, England :
56 1993)*, 16(7), 1105–1115. <https://doi.org/10.1016/j.str.2008.03.017>
- 57 47. Todar, K. G., & University of Wisconsin--Madison,. (2006). *Todar's Online textbook of bacteriology*.
58 Madison, WI: Kenneth Todar, University of Wisconsin-Madison Dept. of Bacteriology.
- 59 48. Byndloss, M. X., Olsan, E. E., Rivera-Chávez, F., Tiffany, C. R., Cevallos, S. A., Lokken, K. L., Torres, T.
60 P., Byndloss, A. J., Faber, F., Gao, Y., Litvak, Y., Lopez, C. A., Xu, G., Napoli, E., Giulivi, C., Tsolis, R. M.,
61 Revzin, A., Lebrilla, C. B., & Bäumler, A. J. (2017). Microbiota-activated PPAR-γ signaling inhibits dysbiotic
62 Enterobacteriaceae expansion. *Science (New York, N.Y.)*, 357(6351), 570–575.
63 <https://doi.org/10.1126/science.aam9949>
- 64 49. Tan, B., Lu, Z., Dong, S., Zhao, G., & Kuo, M. S. (2014). Derivatization of the tricarboxylic acid intermediates
65 with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection. *Analytical
66 biochemistry*, 465, 134–147.
- 67 50. Spees, A. M., Wangdi, T., Lopez, C. A., Kingsbury, D. D., Xavier, M. N., Winter, S. E., Tsolis, R. M., &
68 Bäumler, A. J. (2013). Streptomycin-induced inflammation enhances Escherichia coli gut colonization
69 through nitrate respiration. *mBio*, 4(4), e00430-13. <https://doi.org/10.1128/mBio.00430-13>
- 70
71
72

73 **FIGURE 1**

74

75

76



77

78

79

80

81

82

83

84

85

86


87

88

89

90 **FIGURE 2**

91



92

93

94

95

96

97

98

99

00

01


02

03

04


05

FIGURE 3



18 **FIGURE 4**

19



20

21

22

23

24

25

26

27

28

29


30

31

32

33

34 **FIGURE 5**



35

36

37

38

39

40

41

42

43


44

45

46

47 **FIGURE 6**

48



49

50

51

52

53

54

55

56

57

58 **SUPPLEMENTARY MATERIAL**

59 **Supplemental Table 1. Bacterial strains were used in this study.**

60

Bacterial strains	Source
<i>S. Typhimurium</i> , SL1344 Strep ^R	42
<i>S. Typhimurium</i> , $\Delta prpC$	This study
<i>S. Typhimurium</i> , $\Delta prpC$ <i>phoN</i> ::Kan ^R	This study
<i>S. Typhimurium</i> , $\Delta prpBCDE$	This study
<i>S. Typhimurium</i> , $\Delta prpBCDE$ <i>phoN</i> ::Kan ^R	This study
<i>S. Typhimurium</i> , $\Delta invA$	This study
<i>S. Typhimurium</i> , $\Delta invA\Delta spiB$	This study
<i>S. Typhimurium</i> , $\Delta invA \Delta spiB \Delta prpC$	This study
<i>S. Typhimurium</i> , $\Delta invA \Delta spiB \Delta prpC$ <i>phoN</i> ::Kan ^R	This study
<i>S. Typhimurium</i> , $\Delta napA \Delta narZ$ <i>narG</i> ::pCAL	22
<i>S. Typhimurium</i> , $\Delta napA \Delta narZ$ <i>narG</i> ::pCAL5 <i>phoN</i> ::Kan ^R	22
<i>S. Typhimurium</i> , $\Delta napA \Delta narZ$ <i>narG</i> ::pCAL5 $\Delta prpC$	This study
<i>S. Typhimurium</i> , $\Delta napA \Delta narZ$ <i>narG</i> ::pCAL5 $\Delta prpC$ <i>phoN</i> ::Cm ^R	This study
<i>E. coli</i> , S17-1 λpir , <i>zxx</i> ::RP4 2-(TetR::Mu) (KanR::Tn7) λpir <i>recA1 thi pro hsdR</i> (r-m+)	45
<i>B. thetaiotaomicron</i> , VPI 5482 Δtdk	46
<i>B. thetaiotaomicron</i> , $\Delta tdk \Delta 1686-1689$	38

61

62

Supplemental Table 2. Primers used in this study.

Targeted mutagenesis and complementation	
Purpose	Primer Sequence (5' - 3')
Deletion of <i>prpC</i>	TCTCAAGGGCATCGCTCGATCGTGCGCAGGCTTA
	CGAGGACAATGTGTCGCTGGAAATTCAACA
	CCAGCGACACATTGTCCTCGTCATTATTGT
	GCATAAGGGAGAGCGTGGGTAGACATAGGGTACGT
Confirmation of <i>prpC</i> deletion	CGCGCTGTACAGGAATAAAA
	TAATCGCGGAGTAGACATCC
Deletion of <i>prpBCDE</i>	TCTCAAGGGCATCGGCTATTATCGCGCGGAGCGC
	TGGATGATGTCCGACGGCGCAAATCCGCAA
	GCGCCGTCGGACATCATCCAGCGTAGAAAT
	GCATAAGGGAGAGCGATTTCTCGCGTCCCCAGCCG
Deletion of <i>invA</i>	GTGCTGCTTTCTCTACTTAACAGTGCTCGTTTACGACCTGTGTAGGCTGGAGCTGCTTC
	TTATATTGTTTTTATAACATTCACTGACTTGCTATCTGCTCTGTCAAACATGAGAATTAATTCC
Deletion of <i>spiB</i>	TCCAAAGAGTTCCTGGAAAATACGTTTTTTAGGTCACGTTTGTAGGCTGGAGCTGCTTC
	TCACTTAAAATCTAATGGATAGTTAATCAAAGTATCATAACTGTCAAACATGAGAATTAATTCC
Deletion of <i>prpC</i> in $\Delta invA \Delta spiB$	GCCTCAATACCCTACACATTACAATAATGACGAGGACAATTGTAGGCTGGAGCTGCTTCG
	AAAACCAGTCGAGATTCGGGAACATCTTTTTGGTCTCCCAATTCCGGGGATCCGTCGACC
Complementation of $\Delta prpC$	GGAGAAATTA ACTATGAGAATGACAGACACGACGATCCT
	AGCTTGGCTGCAGGTCGACTTATTTTTAATAAGAGTGAG

RT-qPCR			
Organism	Target gene	Forward primer (5' - 3')	Reverse primer (5' - 3')
S. Tm	<i>prpC</i>	TTCAACGCCTCGACGTTTAC	CCAAAGCCAATCACCACCTC
S. Tm	<i>prpR</i>	CGGCTTTACTTGCCTTTCAG	TGTCAGACGGGTCATATCCA
S. Tm	<i>prpB</i>	GGGATTTCTACGCTGGATGA	CCATCTCCTCTTTCGAGAC
S. Tm	<i>gyrB</i>	ATAACGCCACGCAGAAAATGA	TGGCTGATACACCAGCTCTTTG

<i>Mus musculus</i>	<i>Nos2</i>	TTGGGTCTTGTTCACTCCACGG	CCTCTTTCAGGTCACCTTTGGTAGG
<i>Mus musculus</i>	<i>Act2b</i>	GCTGAGAGGGAAATCGTGCGTG	CCAGGGAGGAAGAGGATGCGG

65

66

67

Supplementary Table 3. Criteria for blinded scoring of histopathological changes

Score	Submucosal edema	Epithelial damage	Exudate	Submucosal neutrophil infiltration (cells/high power field)	Submucosal mononuclear cell infiltration (cells/high power field)
0	No changes	No changes	No changes	No changes (0-5)	No changes (0-5)
1	Detectable (<10%)	Desquamation	Slight focal accumulation	(6-20)	(5-10)
2	Mild (10-20%)	Mild erosion	Mild focal accumulation	(21-60)	(10-20)
3	Moderate (20-40%)	Marked erosion and/or mild ulceration	Moderate multifocal accumulation	(61-100)	(20-40)
4	Marked (>40%)	Multifocal ulceration	Marked diffuse accumulation	(>100)	(>40)

68

69

70

71

72


73

74

75

76

77




78

Figure S1. Disruption to *prpBCDE* operon prevents propionate catabolism during anaerobic respiration.

(A) Complete model of propionate catabolism in *S. Tm*. Genes in the *prpBCDE* operon (red) metabolize propionate into pyruvate. The intermediate propionyl-CoA is also produced by 1, 2 propanediol catabolism (*pdu* operon (grey)). *acs*, acetyl-CoA synthetase, *ackA*, acetate kinase, *pta*, phosphotransferase (blue). (B) NCE minimal media containing 10 mM propionate and 40 mM nitrate was inoculated with wildtype *S. Tm*, $\Delta prpC$, or $\Delta prpBCDE$. OD₆₀₀ of each strain was measured after 24 hours of anaerobic growth. (C) NCE minimal media containing 10 mM propionate, 40 mM nitrate, 10 mM propionate and 40 mM nitrate was inoculated with equal mixture of the *S. Tm* wildtype strain and $\Delta prpBCDE$. The competitive index was determined after 24 hours of anaerobic growth. (D – E) NCE minimal media containing 40 mM glycerol and 40 mM nitrate (D) or NCE minimal media containing 5 mM glucose (E) were inoculated with wildtype *S. Tm*, $\Delta prpC$, or $\Delta prpBCDE$. OD₆₀₀ of each strain was measured after 24 hours of anaerobic growth. Each dot represented one biological replicate. Bars represent the geometric mean. **, $p < 0.01$.

91
92
93
94




95

Figure S2. Low pH decreases *S. Tm* growth during anaerobic respiration. (A) NCE minimal media was adjusted to pH 6.0, 6.5, and 7.0 and either 10 mM propionate or 10 mM propionate + 40 mM nitrate was added. Media was inoculated with wildtype *S. Tm* and grown anaerobically for 24 hours. Fold change calculated by comparing growth of *S. Tm* in media containing propionate alone to *S. Tm* grown with both propionate and nitrate. (B) NCE minimal media was adjusted to pH 6.0, 6.5, and 7.0 and either 40 mM glycerol or 40 mM glycerol + 40 mM nitrate was added. Media was inoculated with wildtype *S. Tm* and grown anaerobically for 24 hours. Fold change calculated by comparing growth of *S. Tm* in media containing glycerol alone to *S. Tm* grown with both glycerol and nitrate. Each dot represents one biological replicate. Bars represent the geometric mean.

96
97
98
99
100
101
102
103
104
105
106
107
108
109

10
11
12
13




14
15

16 **Figure S3. In vitro growth of *Bacteroides* strains.** (A) Mucin broth was inoculated with *B. theta* BT1686-89 and aliquots taken every 24 hours for plating on blood agar. Dots represent mean, error bars represent SD (n = 4). (B) Mucin broth was inoculated with wildtype *B. theta* (WT) or *B. theta* BT1686-89. *B. theta* BT1686-89 was cultured anaerobically for 4 days and wildtype *B. theta* was cultured for 2 days. Growth determined by plating on blood agar. Bars represent mean, error bars represent SD (n = 3).

22
23
24
25
26
27
28

29



30

31

32

33

Figure S4. Schematics of *S. Tm* propionate utilization in the inflamed gut. Upon infection, *S. Tm* (red) uses its' T3SS-1 to invade the intestinal epithelium. Innate immune cells (red) recognize this invasion and produce nitric oxide (NO) that can be converted into nitrate (NO₃⁻). Propionate is produced by microbiota members (blue and gray). We propose *S. Tm* overcomes microbiota-mediated colonization resistance by using propionate as a carbon source to respire via alternative electron acceptors.

37